Everyone Wants a Piece of this Scottish Biotech’s AI

Evotec has doubled down on its investment in Exscientia: the German outfit just announced it has invested €15M to take a minority stake.

Sanofi, GSK and Evotec have all jumped at the opportunity to work with Exscientia, a Scottish startup founded in 2012 and incubating in Dundee. Now, Evotec has gone beyond the initial immuno-oncology deal and invested €15M in Exscientia to accelerate its growth in exchange for a minority stake, making Evotec the first strategic shareholder in the Scotland-based company.  This follows partnerships between Exscientia and two big pharma, Sanofi and most recently GSK that could be worth nearly €300M combined.

AI in biotech has really taken off, particularly for Alzheimer’s research. The biggest name in the European arena is BenevolentAI, whose CEO, Jackie Hunter, I recently interviewed about the company’s strategy. Despite its establishment as a leader with its recent purchase of a NVIDIA supercomputer, BenevolentAI seems to have found a competitor in this Scottish biotech, evidenced by pharma’s interest in the startup.


Image via strelka / shutterstock.com

Previous post

Oxford Spinout goes for $75M IPO on Nasdaq to Fund Gene Therapy Programs

Next post

What are Alphabodies and How Do They Drug the Undruggable?

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.